CJC-1295 (no DAC) + Ipamorelin

What is CJC‑1295 (No DAC) + Ipamorelin?

• CJC‑1295 (No DAC): A truncated GHRH analog that retains GH‑releasing capability but decays in approximately 30 minutes, preserving natural GH pulses [1].
• Ipamorelin: A synthetic pentapeptide (Aib‑His‑D‑2‑Nal‑D‑Phe‑Lys‑NH₂) that selectively activates the ghrelin receptor (GHS-R1a), triggering rapid GH release without elevation of cortisol or prolactin—distinct from other GH secretagogues [3].

Structure

• CJC‑1295 (No DAC): Modified sermorelin‑like peptide lacking DAC, enabling a short half-life of ~30 minutes [1].
• Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH₂; molecular weight ~717 Da; selective ghrelin receptor agonist [3].

Research Highlights

1. Tissue Repair and Metabolism

   Elevated GH/IGF‑1 levels from this peptide combination are associated with increased protein synthesis, improved body composition, and enhanced recovery—though direct studies on the combined use remain preliminary [1][2].

2. Safety Profile

   In clinical trials, CJC‑1295 (No DAC) was well-tolerated with no serious side effects, and Ipamorelin exhibited excellent specificity for GH release without activating other endocrine axes [1][3].

3. Natural Pulsatility Preservation

   Unlike long-acting DAC versions, CJC‑1295 (No DAC) maintains the natural pulsatility of GH, which is crucial for physiological hormone signaling and downstream effects [1].

Disclaimer

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Referenced Citations

1. Teichman SL, Neale A, Lawrence B, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC‑1295, a long‑acting analog of GH‑releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006;91(3):799–805. Available at: https://pubmed.ncbi.nlm.nih.gov/16352683/
2. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. “Prospective, randomized, controlled, proof‑of‑concept study of the ghrelin‑receptor agonist ipamorelin for the management of postoperative ileus in bowel resection patients.” Int J Colorectal Dis. 2014;29(12):1527–1530. Available at: https://pubmed.ncbi.nlm.nih.gov/25331030/
3. Smith RG, et al. “Ipamorelin, the first selective growth hormone secretagogue.” [PubMed PMID: 9849822]. Available at: https://pubmed.ncbi.nlm.nih.gov/9849822/